Biogen Reports Mixed Results of Vixotrigine (BIIB074) in P-II CONVEY Study for the Treatment of Small Fiber Neuropathy

September 17, 2021 Auto Bot Biogen, Clinical Trials, P-II 0

Shots:

  • The P-II CONVEY withdrawal study evaluates efficacy & safety of vixotrigine (200/350 mg, bid) vs PBO in 265 patients with SFN for 12wks.
  • The study met its 1EPs i.e., 200mg dose showed a reduction in mean ADP & worst daily pain score @12wks. while 350mg dose did not meet its 1EPs of mean change in ADP but met statistical significance in PGIC
  • The 2EPs of both doses include a proportion of patients with ≥2-point or improvement in ADP scores with ≥a 30% reduction in ADP @12wks. but the therapy was well-tolerated. The company plan to start a P-III trial based on data from a vixotrigine program

Click here to­ read full press release/ article | Ref: Biogen | Image: The Business Journals

The post Biogen Reports Mixed Results of Vixotrigine (BIIB074) in P-II CONVEY Study for the Treatment of Small Fiber Neuropathy first appeared on PharmaShots.